Cannabinoids Studied for Fatty Liver
New research explores how non-intoxicating cannabinoids such as CBD and CBG may influence metabolic processes linked to fatty liver disease.
A recent study led by Professor Joseph Tam at the Hebrew University of Jerusalem investigates how cannabis-derived compounds may influence Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a chronic liver condition estimated to affect roughly one-third of adults worldwide.
The research focuses on two non-intoxicating cannabinoids—Cannabidiol (CBD) and Cannabigerol (CBG)—and examines how they alter metabolic processes within liver cells. Rather than acting primarily through weight loss, the compounds appear to influence cellular energy balance and lipid handling mechanisms, a process researchers describe as metabolic remodeling.
Importantly, the findings come from preclinical experimental models, meaning further clinical studies are required before therapeutic conclusions can be drawn.
Increased Cellular Energy Reserves: The Phosphocreatine Mechanism
One of the central study observations was an increase in phosphocreatine levels within liver tissue following treatment with CBD and CBG.
The Mechanism
Phosphocreatine is a high-energy molecule best known for supporting rapid energy demands in muscle cells. Under normal conditions, the liver relies less heavily on this system. However, researchers found that cannabinoid exposure enhanced phosphocreatine availability during metabolic stress induced by a high-fat diet.
This effect appears to create an additional cellular energy reserve, helping hepatocytes maintain ATP production when metabolic demand rises.
Observed Effects
By stabilizing cellular energy balance, liver cells showed improved resilience to metabolic stress—a factor associated with reduced progression toward inflammation and fibrosis in MASLD models.
Rather than acting as a direct cure, the mechanism suggests cannabinoids may support energy homeostasis, allowing liver cells to better cope with lipid overload.
Restoration of Lysosomal Function and Lipid Clearance
The study also examined how cannabinoids affect lysosomes—intracellular structures responsible for breaking down waste products and excess lipids.
The Problem in MASLD
In fatty liver disease, lysosomal activity can become impaired, leading to accumulation of triglycerides and bioactive lipids such as ceramides, which are associated with insulin resistance and inflammatory signaling.
Study Findings
CBD and CBG increased the activity of cathepsins, enzymes that drive lysosomal degradation processes. Enhanced enzyme activity was linked with:
- Reduced liver triglyceride levels
- Lower concentrations of harmful types of lipids
- Improved metabolic markers in experimental models
These findings suggest cannabinoids may indirectly improve liver metabolism by restoring cellular “cleanup” pathways rather than directly blocking fat production.
Comparative Effects of CBD and CBG
Both cannabinoids produced measurable metabolic changes, although the study reported some differences between them.
CBD:
- Reduced lipid accumulation in liver tissue
- Contributed to improved inflammatory and metabolic markers
CBG:
- Produced stronger effects on cholesterol reduction
- Improved insulin sensitivity more noticeably
- Reduced overall body fat mass in the experimental models
Researchers did not conclude that one compound is universally superior; instead, results suggest partially distinct metabolic targets that may be complementary.
Technical Perspective: Energy Balance and Metabolic Flux
Using metabolic flux analysis, researchers tracked how cannabinoids influenced hepatic energy dynamics. A key observation was improvement in the ATP-to-ADP ratio, an indicator of cellular energy status during metabolic stress.
The proposed sequence is:
- CBD and CBG increase phosphocreatine availability.
- Phosphocreatine buffers ATP depletion during lipid overload.
- Stable energy supply supports lysosomal enzyme activity.
- Improved lysosomal function enhances lipid breakdown and cellular maintenance.
Together, these changes form the basis of the proposed “metabolic remodeling” effect described by the authors.
Context and Limitations
While the results are mechanistically significant, several limitations should be emphasized:
- The research was conducted in controlled preclinical models rather than human clinical trials.
- Effective dosing, long-term safety, and therapeutic applicability in humans remain unknown.
- MASLD is a multifactorial disease strongly influenced by diet, physical activity, genetics, and metabolic health.
The authors note that additional clinical research will be necessary before cannabinoid-based treatments can be considered for medical use.
Why the Findings Matter
MASLD currently has limited pharmacological treatment options, with management largely focused on lifestyle interventions such as weight reduction and metabolic control.
This study contributes to growing research exploring how modulation of cellular energy systems—rather than only fat reduction—might influence disease progression. The identification of phosphocreatine-mediated metabolic support represents a newly described pathway linking cannabinoids to liver metabolism.
Rather than demonstrating a ready-to-use therapy, the study provides insight into how cannabinoids may influence fundamental metabolic processes in the liver, offering a foundation for future clinical investigation.
Read more from Soft Secrets:
S
Stephen Andrews
